Cardiotoxicity induced by tyrosine kinase inhibitors

Figures & data

Table I.  Comprehensive presentation of the tyrosine kinase inhibitors on clinical use, their targets, indications and type of cardiac toxicity

Agent	Tyrosine kinase targets	Indications	Type of cardiac toxicity
Imatinib mesylate	Bcr-Abl, c-kit, PDGFR-α and β	CML, Ph + ALL, GIST, CMML, CEL, DFSP	CHF, LVEF depression
Dasatinib	Bcr-Abl, c-kit, PDGFR-α and β, Src Family	CML	QT prolongation, Peripheral oedema, pericardial effusion
Nilotinib	Bcr-Abl, c-kit, PDGFR-α and β	CML	QT prolongation
Sunitinib	VEGFR 1-3, RET, PDGFR-α and β, c-kit, FLT3, CSF1R	RCC, GIST	Hypertension, LVEF depression, CHF, MI
Sorafenib	VEGFR 2&3, c-kit, PDGFR β, FLT3, RAF1, BRAF	RCC,HCC	Acute coronary syndrome, MI, Hypertension
Lapatinib	EGFR, ERBB2	Breast Ca	Asymptomatic LVEF depression
Gefitinib	EGFR	NSCLC
Erlotinib	EGFR	NSCLC, Ca pancreas